Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited (NASDAQ: KZIA) files as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily using Form 20-F for annual reporting and Form 6-K for current reports. This SEC filings page for KZIA brings together those regulatory documents and pairs them with AI-generated summaries to help readers interpret the company’s disclosures.
For a clinical-stage oncology company like Kazia, Form 6-K reports often incorporate press releases and transaction details by reference. Recent 6-K filings describe private placements of equity securities, the terms of pre-funded warrants and American Depositary Shares, at-the-market offering agreements, and collaboration and in-licensing arrangements such as the PD-L1 protein degrader program with QIMR Berghofer. Other 6-Ks discuss Nasdaq listing notices, the company’s responses, and subsequent steps taken to regain or demonstrate compliance with listing standards.
These filings also reference how capital raised is intended to support the continued clinical development of Kazia’s lead programs, including paxalisib, a brain-penetrant PI3K / Akt / mTOR pathway inhibitor, and EVT801, a VEGFR3 inhibitor, as well as the PD-L1 degrader program. Supplemental risk factor disclosures in certain filings provide additional detail on regulatory approval processes, combination therapy development, and ongoing regulatory obligations after any potential approvals.
On this page, AI-powered tools can help explain the structure and implications of Kazia’s 6-K filings, highlight key terms in financing agreements, and summarize how new collaborations or regulatory updates relate to the company’s oncology pipeline. Users can also review references to incorporated press releases, understand how offerings may affect capital structure, and see how Kazia describes its strategy for maintaining Nasdaq listing and advancing its investigational cancer therapies.
Kazia Therapeutics Ltd ownership filing: Jorey Chernett reports beneficial ownership of 1,412,662 ADS, representing 12.46% of the American Depositary Shares as of
The filing is an amendment to a previously reported Schedule 13G and lists the Reporting Person's principal business address in Bloomfield Hills, Michigan, and U.S. citizenship.
Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G reporting a 5.1% beneficial stake in Kazia Therapeutics Limited. They report beneficial ownership of 580,754 American Depositary Shares, each ADS representing five-hundred ordinary shares of Kazia.
The ADSs may be acquired within 60 days by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts advised by Ikarian Capital. The holders state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Kazia.
Kazia Therapeutics Ltd received an amended Schedule 13G filing from Dauntless Investment Group, LLC covering its holdings of Kazia American Depositary Shares. As of the event date of 12/31/2025, Dauntless reports beneficial ownership of 1 American Depositary Share, representing 0.0% of the class.
Dauntless reports no sole or shared voting power over any shares and sole dispositive power over 1 share. The filer identifies itself as a single family office/passive investor and certifies that the securities are not held for the purpose of changing or influencing control of Kazia.
Kazia Therapeutics Limited files a prospectus supplement covering 266,666 American Depositary Shares, representing 133,333,000 ordinary shares, and updates investors using a newly furnished Form 6-K.
The attached report highlights encouraging early results from an ongoing Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer. Three patients treated with paxalisib-based regimens have shown meaningful clinical responses, including two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient.
Paxalisib in combination with pembrolizumab and chemotherapy has been generally well tolerated, with most adverse events deemed unlikely or unrelated to paxalisib and reported paxalisib-related events mainly mild to moderate. Kazia plans to activate additional clinical sites in 2026, aims to enroll twelve triple-negative breast cancer patients by the end of 2026, and anticipates topline data in early 2027.
Kazia Therapeutics Limited files a prospectus supplement covering 95,110 American Depositary Shares (ADSs), which represent 47,555,000 ordinary shares, to update its existing Form F‑1 prospectus with new clinical information from a recent Form 6‑K. The update centers on a Phase 1b study of paxalisib in late‑stage metastatic triple‑negative breast cancer (TNBC) in combination with pembrolizumab and chemotherapy.
In this program, three patients with metastatic TNBC treated with paxalisib‑based regimens have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated, with most adverse events considered unlikely or unrelated to the drug and only expected, mainly mild to moderate, paxalisib‑related side effects reported at the 30 mg daily dose.
Kazia plans to activate two additional clinical sites by April 2026 and two more in mid‑2026, targeting enrollment of twelve TNBC patients by the end of 2026 and a topline data readout in early 2027, while continuing broader development of paxalisib and other oncology assets.
Kazia Therapeutics Limited supplements its prospectus covering 232,956 American Depositary Shares, each representing 500 ordinary shares, with a new clinical update on paxalisib in metastatic triple-negative breast cancer (TNBC). The attached Form 6-K details preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy or with olaparib in advanced breast cancer. Three metastatic TNBC patients have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient, all remaining on treatment. Paxalisib has been generally well tolerated at a 30 mg daily dose, with mostly mild to moderate expected side effects and two serious adverse events reported as unrelated to paxalisib. Kazia plans to activate additional clinical sites in 2026, target enrollment of twelve TNBC patients by the end of 2026, and expects topline data in early 2027.
Kazia Therapeutics Limited has a prospectus supplement covering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares, and uses it to incorporate a new clinical update into its existing Form F-1 prospectus. The supplement attaches a Form 6-K that reports preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer.
The company notes three meaningful clinical responses so far: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated with mostly mild to moderate expected side effects, and Kazia plans to activate additional clinical sites in 2026, complete enrollment of twelve TNBC patients by the end of 2026, and target a topline data readout in early 2027.
Kazia Therapeutics reported early clinical signals from an ongoing Phase 1b study of its PI3K/mTOR inhibitor paxalisib in late-stage metastatic triple-negative breast cancer. The drug is being tested with pembrolizumab and chemotherapy, or with olaparib in BRCA-mutated advanced breast cancer. Three metastatic TNBC patients treated with paxalisib-based regimens have shown meaningful responses, including two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient. Paxalisib has been generally well tolerated, with about 75% of adverse events judged unlikely or unrelated to the drug, mainly mild to moderate expected side effects, one Grade 1 hyperglycemia case, and two serious adverse events deemed unrelated. Kazia plans to activate additional clinical sites in 2026, aims to enroll twelve TNBC patients by the end of 2026, and anticipates a topline data readout in early 2027.
Lynwood Opportunities Master Fund and its affiliates have disclosed a sizable passive stake in Kazia Therapeutics Limited. The fund, together with its investment manager Lynwood Capital Management Inc. and principal Ben Shapiro, reports beneficial ownership of 307,998,500 Ordinary Shares, representing 5.4% of Kazia’s Ordinary Shares as of the close of business on January 15, 2026. This percentage is based on 5,667,995,734 Ordinary Shares outstanding as of December 11, 2025.
The position is held through Kazia’s American Depositary Shares, each representing 500 Ordinary Shares, under CUSIP 48669G303. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Kazia, indicating a passive investment stance.
Kazia Therapeutics Limited is registering for resale up to 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares, held by existing investors. These ADSs consist of ordinary shares and ADSs issuable upon exercise of pre-funded warrants originally sold in a prior private placement, and all sale proceeds will go to the selling shareholders, not the company.
Kazia is an oncology-focused biotech developing paxalisib for glioblastoma and other brain cancers, and EVT801 for solid tumors. In December 2025, the company completed a private placement of 4,530,854,000 ordinary shares and pre-funded warrants to purchase up to 938,490 ADSs, generating approximately $46.5 million in net proceeds, which management expects will fund operations into the second half of 2028. Nasdaq has also confirmed that Kazia’s ADSs remain in compliance with listing standards after a prior deficiency related to market value of listed securities.